Literature DB >> 25671839

Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.

Alejandra Villamil1, Eduardo Mullen1, Paola Casciato1, Adrian Gadano1.   

Abstract

Type I interferons are potent cytokines that possess antiviral, immunomodulating and antiproliferative actions. The development of autoimmune hepatitis is a well recognized complication of treatment with alpha IFN in patients with chronic viral hepatitis. Yet, the occurrence in patients under treatment with beta IFN for other indications is controversial and its occurrence often underestimated. We report two cases of severe acute autoimmune hepatitis in two patients undergoing therapy with IFN beta 1a for multiple sclerosis who recovered under early immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25671839

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  7 in total

1.  Autoimmune hepatitis induced by a single injection of interferon-β 1a in a patient with multiple sclerosis.

Authors:  Hiroki Yamaguchi; Kenji Sakai; Yoshinori Goto; Masahito Yamada
Journal:  J Neurol       Date:  2018-05-29       Impact factor: 4.849

2.  "Lupoid hepatitis" in SLE patients and mice with experimental lupus.

Authors:  Stepan Shumyak; Li-Jun Yang; Shuhong Han; Haoyang Zhuang; Westley H Reeves
Journal:  Clin Immunol       Date:  2016-07-16       Impact factor: 3.969

Review 3.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

Review 4.  Recent Advances in the Histopathology of Drug-Induced Liver Injury.

Authors:  David E Kleiner
Journal:  Surg Pathol Clin       Date:  2018-06

5.  An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a.

Authors:  Yuichi Yamazaki; Aya Suzuki; Kimitoshi Hirayanagi; Yusuke Tsukagoshi; Ryota Uehara; Kazuhiko Horiguchi; Tatsuya Ohyama; Takuya Tomaru; Norio Horiguchi; Sumihito Nobusawa; Hayato Ikota; Ken Sato; Satoru Kakizaki; Motoyasu Kusano; Yoshio Ikeda; Hideaki Yokoo; Masanobu Yamada
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

6.  Design, synthesis, and biological evaluation of N-arylpiperazine derivatives as interferon inducers.

Authors:  Yeonjeong Chu; B Raja Sekhara Reddy; V Pratap Reddy Gajulapalli; K Sudhakar Babu; Eunha Kim; Sanghee Lee
Journal:  Bioorg Med Chem Lett       Date:  2020-10-16       Impact factor: 2.823

Review 7.  The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.

Authors:  Marco Biolato; Assunta Bianco; Matteo Lucchini; Antonio Gasbarrini; Massimiliano Mirabella; Antonio Grieco
Journal:  CNS Drugs       Date:  2021-07-28       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.